Cargando…

Neuroprotection by the Immunomodulatory Drug Pomalidomide in the Drosophila LRRK2(WD40) Genetic Model of Parkinson’s Disease

The search for new disease-modifying drugs for Parkinson’s disease (PD) is a slow and highly expensive process, and the repurposing of drugs already approved for different medical indications is becoming a compelling alternative option for researchers. Genetic variables represent a predisposing fact...

Descripción completa

Detalles Bibliográficos
Autores principales:	Casu, Maria Antonietta, Mocci, Ignazia, Isola, Raffaella, Pisanu, Augusta, Boi, Laura, Mulas, Giovanna, Greig, Nigel H., Setzu, Maria Dolores, Carta, Anna R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7031158/ https://www.ncbi.nlm.nih.gov/pubmed/32116655 http://dx.doi.org/10.3389/fnagi.2020.00031

Ejemplares similares

Improvements of Motor Performances in the Drosophila LRRK2 Loss-of-Function Model of Parkinson’s Disease: Effects of Dialyzed Leucocyte Extracts from Human Serum
por: Diana, Andrea, et al.
Publicado: (2020)

Repurposing Pomalidomide as a Neuroprotective Drug: Efficacy in an Alpha-Synuclein-Based Model of Parkinson’s Disease
por: Palmas, Maria Francesca, et al.
Publicado: (2022)

Modeling Parkinson’s Disease Neuropathology and Symptoms by Intranigral Inoculation of Preformed Human α-Synuclein Oligomers
por: Boi, Laura, et al.
Publicado: (2020)

Effects of memantine on mania‐like phenotypes exhibited by Drosophila Shaker mutants
por: Mocci, Ignazia, et al.
Publicado: (2023)

The WD40 Domain Is Required for LRRK2 Neurotoxicity
por: Jorgensen, Nathan D., et al.
Publicado: (2009)

Crystal structure of the WD40 domain dimer of LRRK2
por: Zhang, Pengfei, et al.
Publicado: (2019)

Repurposing Immunomodulatory Imide Drugs (IMiDs) in Neuropsychiatric and Neurodegenerative Disorders
por: Jung, Yoo Jin, et al.
Publicado: (2021)

Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma
por: Chanan-Khan, A A, et al.
Publicado: (2013)

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
por: Lopez-Girona, A, et al.
Publicado: (2012)

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
por: Lopez-Girona, A, et al.
Publicado: (2012)

Deletion of the WD40 Domain of LRRK2 in Zebrafish Causes Parkinsonism-Like Loss of Neurons and Locomotive Defect
por: Sheng, Donglai, et al.
Publicado: (2010)

A Novel LRRK2 Variant p.G2294R in the WD40 Domain Identified in Familial Parkinson’s Disease Affects LRRK2 Protein Levels
por: Ogata, Jun, et al.
Publicado: (2021)

Population Pharmacokinetics of Pomalidomide
por: Li, Yan, et al.
Publicado: (2015)

Therapeutic effect of the immunomodulatory drug lenalidomide, but not pomalidomide, in experimental models of rheumatoid arthritis and inflammatory bowel disease
por: Lopez-Millan, Belen, et al.
Publicado: (2017)

Pomalidomide-induced hypothyroidism
por: Ali, Sulaiman Haji, et al.
Publicado: (2017)

Pomalidomide Reduces Ischemic Brain Injury in Rodents
por: Tsai, Yan-Rou, et al.
Publicado: (2019)

Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy?
por: Carta, Anna R., et al.
Publicado: (2011)

Functional and Morphological Correlates in the Drosophila LRRK2 loss-of-function Model of Parkinson’s Disease: Drug Effects of Withania somnifera (Dunal) Administration
por: De Rose, Francescaelena, et al.
Publicado: (2016)

Metabolomics Fingerprint Induced by the Intranigral Inoculation of Exogenous Human Alpha-Synuclein Oligomers in a Rat Model of Parkinson’s Disease
por: Murgia, Federica, et al.
Publicado: (2020)

Pomalidomide for the Treatment of Multiple Myeloma
por: Clark, Stephen M., et al.
Publicado: (2014)

Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy
por: Ríos-Tamayo, Rafael, et al.
Publicado: (2017)

LRRK2 and Proteostasis in Parkinson’s Disease
por: Pérez-Carrión, María Dolores, et al.
Publicado: (2022)

Spotlight on pomalidomide: could less be more?
por: Zander, T, et al.
Publicado: (2017)

Expression Analysis of Lrrk1, Lrrk2 and Lrrk2 Splice Variants in Mice
por: Giesert, Florian, et al.
Publicado: (2013)

Combined measure of salivary alpha-synuclein species as diagnostic biomarker for Parkinson’s disease
por: Angius, Fabrizio, et al.
Publicado: (2023)

Profile of pomalidomide and its potential in the treatment of myelofibrosis
por: Gowin, Krisstina L, et al.
Publicado: (2015)

Pomalidomide-Induced Pulmonary Toxicity in Multiple Myeloma
por: Modi, Dipenkumar, et al.
Publicado: (2015)

Genome-wide analysis of WD40 protein family and functional characterization of BvWD40-82 in sugar beet
por: Wu, Zhirui, et al.
Publicado: (2023)

Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myeloma
por: Fotiou, Despina, et al.
Publicado: (2022)

Neuroprotection by immunomodulatory agents in animal models of Parkinson’s disease
por: Martinez, Bridget, et al.
Publicado: (2018)

Neuroprotective and Immunomodulatory Action of the Endocannabinoid System under Neuroinflammation
por: Kasatkina, Ludmila A., et al.
Publicado: (2021)

Distribution of pomalidomide into semen of healthy male subjects after multiple doses
por: Li, Yan, et al.
Publicado: (2018)

From Synaptic Dysfunction to Neuroprotective Strategies in Genetic Parkinson’s Disease: Lessons From LRRK2
por: Mancini, Andrea, et al.
Publicado: (2020)

Pomalidomide mitigates neuronal loss, neuroinflammation, and behavioral impairments induced by traumatic brain injury in rat
por: Wang, Jin-Ya, et al.
Publicado: (2016)

WDSPdb: an updated resource for WD40 proteins
por: Ma, Jing, et al.
Publicado: (2019)

New drugs in multiple myeloma – role of carfilzomib and pomalidomide
por: Jurczyszyn, Artur, et al.
Publicado: (2014)

Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma
por: Sivaraj, Dharshan, et al.
Publicado: (2018)

Pomalidomide-induced lung injury: A case report
por: Vivien, Alexandre, et al.
Publicado: (2023)

Erratum to: Pomalidomide mitigates neuronal loss, neuroinflammation, and behavioral impairments induced by traumatic brain injury in rat
por: Wang, Jing-Ya, et al.
Publicado: (2016)

The LuWD40-1 Gene Encoding WD Repeat Protein Regulates Growth and Pollen Viability in Flax (Linum Usitatissimum L.)
por: Kumar, Santosh, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_v8c3gnmqj4pqjr167fi2bpl08s